New Covid-19 treatments should be widely available in France before the end of the year, the head of the country's Scientific Council has predicted.
According to a report in Le Parisien newspaper, Jean-François Delfraissy, an immunologist and president of the Conseil scientifique, which advises the government on medical matters, said monoclonal and polyclonal antibody treatments would be made more widely available in the coming months.
Monoclonal antibody treatments are made using Covid-19 survivors’ own antibodies and are designed to fight infection just as the natural immune system would. Former US President Donald Trump received monoclonal antibody drugs when he was hospitalised with Covid-19 in 2020.
At the beginning of August, French health authorities authorised the use of monoclonal antibody treatments for immuno-compromised patients who cannot be vaccinated against the virus because of their conditions.
The treatments are set to be rolled out for use as required by doctors among the wider population before the end of the year. A number of pharmaceutical companies are in the process of applying for medical authorisation.
They would be “effective for high-risk patients, and should reduce the number of hospitalisations”, Le Parisien reported, but would only be available under medical supervision.
The drugs are intended for use in patients who are already severely ill with Covid. They do not prevent people developing the illness in the first place.
*Image by Klaus Hausmann from Pixabay